Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB), (“Q32 Bio”) a clinical stage biotechnology company focused on developing... Read more.
Pivoting from Trump to a Future Where We All Thrive
WASHINGTON, July 14, 2026 /PRNewswire/ — Since the 2024 election, Donald Trump and both political parties have denied 77 percent of Americans the major political... Read more.
GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
TAIPEI and SAN DIEGO, July 14, 2026 /PRNewswire/ — GEM Global Yield LLC SCS (“GEM”) has executed a Share Purchase Agreement (the “SPA”)... Read more.
LONGi Makes S&P Global Energy Premier List of Tier 1 Cleantech Companies 2026
XI’AN, China, July 14, 2026 /PRNewswire/ — LONGi Green Energy Technology Co., Ltd., one of the world’s leading Solar-plus-Storage companies, has... Read more.
A Hitachi Group site selected as “Global Lighthouse Factory” by the World Economic Forum, marking the Group’s second designation
Hitachi Vantara’s Norman, Oklahoma, U.S. advanced storage manufacturing site newly selected as a “Lighthouse” in recognition of the results achieved... Read more.
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico’s Pharma.AI platform with Bora’s global development, manufacturing, quality, and commercialization capabilities to explore a next-generation... Read more.
Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage... Read more.
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated... Read more.
Space for Humanity’s “Take Off in Zero-G” to Inspire the Next Generation of Global Space Communicators
WASHINGTON, July 14, 2026 /PRNewswire/ — Tomorrow is the final day to apply for Space for Humanity’s “Take Off in Zero-G,” a new initiative... Read more.
RICHARD BECOMES EMPLOYEE-OWNED THROUGH NEW ESOP
CHICAGO, July 14, 2026 /PRNewswire/ — Richard, a veteran-founded national general contracting and construction management firm, today announced it is now an... Read more.